The global market for polyclonal antibodies is projected to grow from US$ 1.68 billion in 2024 to US$ 1.76 billion in 2025, with an estimated value of around US$ 2.74 billion by 2034. This represents a compound annual growth rate (CAGR) of 5.04% between 2025 and 2034. The rise in disease cases is one of the major drivers behind the increasing demand for polyclonal antibodies.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5388

What Are Polyclonal Antibodies?

Polyclonal antibodies (pAbs) are a type of antibody produced by the immune system’s B cells, recognizing different parts (epitopes) on a single antigen. This is in contrast to monoclonal antibodies (mAbs), which target a specific epitope. Polyclonal antibodies are crucial in various applications, from fundamental research to diagnostic processes in medicine, as well as quality control in food processing. They are also used in treating several diseases, possibly offering anti-inflammatory or immune-modulating effects.

Key Trends in the Polyclonal Antibodies Market

• Expansion of Research and Production Facilities:
  In November 2024, Sanofi announced a €40 million (US$42 million) investment in its bioproduction facility in Lyon, France. A significant portion, €25 million (US$26 million), will go into research and production of Thymoglobulin, a polyclonal antibody used for transplant recipients.
• Strategic Acquisitions and Funding:
  In October 2024, EQT Life Sciences revealed that its LSP 7 fund had acquired ATB Therapeutics. The acquisition, which included a €54 million Series A funding round, aims to accelerate the development of a new therapeutic antibody pipeline, leveraging the company’s innovative ATBioFarm technology.
• AI Advancements in Antibody Development:
  Artificial intelligence (AI) is becoming a game-changer in the polyclonal antibody market. By utilizing AI, researchers can predict an antibody’s ability to enter cells and enhance key attributes such as toxicity, immunogenicity, solubility, and half-life, ultimately improving drug development efficiency.